|
Name |
Andrastin D
|
Molecular Formula | C26H36O5 | |
IUPAC Name* |
methyl (5S,8S,9S,10R,13R,14R)-17-hydroxy-4,4,8,10,12,13,16-heptamethyl-3,15-dioxo-1,2,5,6,7,9-hexahydrocyclopenta[a]phenanthrene-14-carboxylate
|
|
SMILES |
CC1=C[C@H]2[C@@]3(CCC(=O)C([C@H]3CC[C@@]2([C@]4([C@@]1(C(=C(C4=O)C)O)C)C(=O)OC)C)(C)C)C
|
|
InChI |
InChI=1S/C26H36O5/c1-14-13-17-23(5)11-10-18(27)22(3,4)16(23)9-12-24(17,6)26(21(30)31-8)20(29)15(2)19(28)25(14,26)7/h13,16-17,28H,9-12H2,1-8H3/t16-,17+,23-,24+,25+,26-/m1/s1
|
|
InChIKey |
SMUNNMAWNRFDPB-UWWAQUNASA-N
|
|
Synonyms |
Andrastin D; DTXSID80894025; CHEBI:142874; methyl (5S,8S,9S,10R,13R,14R)-17-hydroxy-4,4,8,10,12,13,16-heptamethyl-3,15-dioxo-1,2,5,6,7,9-hexahydrocyclopenta[a]phenanthrene-14-carboxylate; Q63399727; 184432-08-4; methyl (5beta,8alpha,9beta,10alpha,13alpha)-15-hydroxy-4,4,8,12,16-pentamethyl-3,17-dioxoandrosta-11,15-diene-14-carboxylate; methyl 15-hydroxy-4,4,8alpha,12,16-pentamethyl-3,17-dioxo-5beta,9beta,10alpha,13alpha-androsta-11,15-diene-14-carboxylate
|
|
CAS | NA | |
PubChem CID | 10477690 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 428.6 | ALogp: | 4.3 |
HBD: | 1 | HBA: | 5 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 80.7 | Aromatic Rings: | 4 |
Heavy Atoms: | 31 | QED Weighted: | 0.347 |
Caco-2 Permeability: | -5.168 | MDCK Permeability: | 0.00001880 |
Pgp-inhibitor: | 0.94 | Pgp-substrate: | 0.004 |
Human Intestinal Absorption (HIA): | 0.032 | 20% Bioavailability (F20%): | 0.925 |
30% Bioavailability (F30%): | 0.951 |
Blood-Brain-Barrier Penetration (BBB): | 0.942 | Plasma Protein Binding (PPB): | 73.85% |
Volume Distribution (VD): | 0.546 | Fu: | 24.67% |
CYP1A2-inhibitor: | 0.021 | CYP1A2-substrate: | 0.954 |
CYP2C19-inhibitor: | 0.178 | CYP2C19-substrate: | 0.918 |
CYP2C9-inhibitor: | 0.151 | CYP2C9-substrate: | 0.089 |
CYP2D6-inhibitor: | 0.002 | CYP2D6-substrate: | 0.116 |
CYP3A4-inhibitor: | 0.754 | CYP3A4-substrate: | 0.849 |
Clearance (CL): | 7.555 | Half-life (T1/2): | 0.636 |
hERG Blockers: | 0.002 | Human Hepatotoxicity (H-HT): | 0.111 |
Drug-inuced Liver Injury (DILI): | 0.714 | AMES Toxicity: | 0.047 |
Rat Oral Acute Toxicity: | 0.678 | Maximum Recommended Daily Dose: | 0.075 |
Skin Sensitization: | 0.05 | Carcinogencity: | 0.857 |
Eye Corrosion: | 0.982 | Eye Irritation: | 0.641 |
Respiratory Toxicity: | 0.958 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001949 | 0.717 | D04GJN | 0.284 | ||||
ENC002012 | 0.632 | D0V2JK | 0.260 | ||||
ENC004115 | 0.620 | D0Q4SD | 0.260 | ||||
ENC003138 | 0.558 | D0I2SD | 0.252 | ||||
ENC005963 | 0.496 | D0X4RS | 0.250 | ||||
ENC003457 | 0.479 | D0H2MO | 0.248 | ||||
ENC005965 | 0.446 | D06AEO | 0.246 | ||||
ENC005964 | 0.441 | D0IX6I | 0.246 | ||||
ENC003565 | 0.417 | D02CNR | 0.244 | ||||
ENC005403 | 0.416 | D06IIB | 0.241 |